Correlation Between Ocuphire Pharma and Sangamo Therapeutics

Can any of the company-specific risk be diversified away by investing in both Ocuphire Pharma and Sangamo Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ocuphire Pharma and Sangamo Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Ocuphire Pharma and Sangamo Therapeutics, you can compare the effects of market volatilities on Ocuphire Pharma and Sangamo Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ocuphire Pharma with a short position of Sangamo Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ocuphire Pharma and Sangamo Therapeutics.

Diversification Opportunities for Ocuphire Pharma and Sangamo Therapeutics

-0.45

Correlation Coefficient

Ocuphire Pharma  Sangamo Therapeutics

Very good diversification

The 3 months correlation between Ocuphire and Sangamo is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding Ocuphire Pharma and Sangamo Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sangamo Therapeutics and Ocuphire Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ocuphire Pharma are associated (or correlated) with Sangamo Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sangamo Therapeutics has no effect on the direction of Ocuphire Pharma i.e., Ocuphire Pharma and Sangamo Therapeutics go up and down completely randomly.

Pair Corralation between Ocuphire Pharma and Sangamo Therapeutics

Given the investment horizon of 90 days Ocuphire Pharma is expected to under-perform the Sangamo Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Ocuphire Pharma is 2.48 times less risky than Sangamo Therapeutics. The stock trades about -0.1 of its potential returns per unit of risk. The Sangamo Therapeutics is currently generating about 0.18 of returns per unit of risk over similar time horizon. If you would invest  85.00  in Sangamo Therapeutics on September 13, 2024 and sell it today you would earn a total of  109.00  from holding Sangamo Therapeutics or generate 128.24% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	49.21%
Values	Daily Returns

Ocuphire Pharma  vs.  Sangamo Therapeutics

Ocuphire Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Ocuphire Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with inconsistent performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Sangamo Therapeutics

Risk-Adjusted Performance

14 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Sangamo Therapeutics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain primary indicators, Sangamo Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Ocuphire Pharma and Sangamo Therapeutics

The main advantage of trading using opposite Ocuphire Pharma and Sangamo Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ocuphire Pharma position performs unexpectedly, Sangamo Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will offset losses from the drop in Sangamo Therapeutics' long position.

The idea behind Ocuphire Pharma and Sangamo Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.